Smart Sensory Technology in Psychotherapy for Pediatric OCD
SSTeP-KiZ
Smart Sensory Technology in Telepsychotherapy for the Treatment of Obsessive-compulsive Disorder in Children and Adolescents
1 other identifier
interventional
20
1 country
1
Brief Summary
Telemedicine interventions enable the improvement of behavioral state-of-the-art treatment of OCD, as therapy can be delivered in the patients' immediate home environment, allowing for more valid symptom actualization. In addition, access to experts is made possible even in rural areas, and the inhibition to seek therapy can be reduced. In a preliminary study, our research group was able to demonstrate the efficiency of using telemedical access. SSTeP-KiZ aims at the further development of telemedical treatment of children with OCD by using sensor technology in the home setting, where most symptoms occur. In this context, relevant emotional states of the patients such as anxiety and stress reactions shall be quantified reliably during the therapy session with exposures by combining different sensor modalities. As a result, the therapy procedure can be immediately and individually adapted to the patient and the situation, thus optimizing the success of the treatment. Methods: It is planned to establish the therapy system on a sample of 10 healthy children and 5-10 patients with OCD treated at University Hospital of Tübingen. Afterwards we will recruit 26 children with obsessive-compulsive disorder aged 12-18 years to conduct therapy with them. There are 14 weekly therapy sessions via teleconferencing with the children and parents. During the sessions and exposures, patients' field of view is recorded via eye trackers, measures of stress responses via heart rate and pupillometry, and movement measures for approach-avoidance behaviors. Using an AI approach, these indicators are integrated and reported back to the therapist online to optimize the therapy process. Accompanying app-based daily symptoms will also be collected by the children and parents and processed for use in the therapy process. We expect a good feasibility and significant symptom reduction by this therapeutic approach and the chance to make this system usable for broad clinical application.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2021
CompletedFirst Submitted
Initial submission to the registry
December 10, 2021
CompletedFirst Posted
Study publicly available on registry
March 22, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2023
CompletedSeptember 29, 2023
September 1, 2023
1.7 years
December 10, 2021
September 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (15)
System Usability Scale (SUS) - assessment of the change in the handling of the technical equipment during treatment
Patients are to answer a total of 60 questions with 10 questions for each technical device from the system usability scale (SUS), regarding the handling of the technical equipment and to capture the change in it.
After week 1, week 7 and week 14
Therapy Process Questionnaire (TPQ) - assessing the stability of the therapeutic relationship and possible changes in the treatment process
Patients are to rate how they perceive the therapeutic process.
Weekly after each therapy session, for 14 weeks of therapy
Client Satisfaction Questionnaire-8 (CSQ-8)
We assess participant's perceptions of the value of the treatment they received
After the last session in week 14 (post treatment)
Questionnaire for the evaluation of the treatment (FBB)
It records how satisfied the participants were with the treatment. We reduced the total number of questions from 20 to 17, as 3 items covered circumstances that did not occur in the context of internet-based therapy.
After the last session in week 14 (post treatment)
Change in Health Care Utilization, measured by HCU-Q (Health Care Utilization-Questionnaire)
Questionnaire to capture costs and time spent on online-based treatments; Health Care Utilization-Questionnaire, change is assessed between baseline and the last session.
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Change in Quality of Life: EQ-5D-3L (European Quality of Life Five Dimensions Questionnaire)
Questionnaire to capture costs and time spent on online-based treatments: Questionnaire to capture costs and time spent on online-based treatments, measured by European Quality of Life Five Dimensions Questionnaire Three Level Version (EQ-5D-3L).
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Change in costs spent on online interventions: CIIQ (Caregiver Indirect and Informal Care Cost Assessment Questionnaire)
Questionnaire to capture costs and time spent on online-based treatments: Caregiver Indirect and Informal Care Cost Assessment Questionnaire (CIIQ)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Change in affinity for technology (TA-EG)
Technology Affinity Questionnaire (TA-EG): The TA-EG can be answered by patients and their parents and contains 19 items. It measures the attitude towards and use of electronic devices.
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Change in attitudes toward and satisfaction with telemedicine psychotherapy (EZtP)
Questionnaire on the Attitude and Satisfaction of Telemedicine Psychotherapy (EZtP). The EZtP is a self-developed questionnaire that measures attitudes to and satisfaction with telemedicine psychotherapy. It can be answered by both the adolescents and the parents.
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Barriers to Treatment Participation Scale (BTPS)
The Barriers to Treatment Participation Scale, is a 44 item rating of how much parents agree with statements about their expectancies of barriers to treatment participation for their child, using a 5-point Likert scale (1=totally disagree, 5= totally agree).
Once after treatment (t1, after 14 weeks)
Measures of feasibility: Manual Rating Form (MRF)
The Manual Rating Form (MRF) is used to assess feasibility of the manual.
Once after treatment (t1, after 14 weeks)
Measures of feasibility: Summary Therapist Feedback Form (STFF)
The Summary Therapist Feedback Form (STFF) is used to assess the ease of manual implementation completed after each case.
Once after treatment (t1, after 14 weeks)
Implementation and satisfaction questionnaire for the children
We designed an implementation and satisfaction questionnaire for the children. It covers the subject's dosage, quality, adaption, responsiveness and program differentiation.
Once after treatment (t1, after 14 weeks)
Implementation and satisfaction questionnaire for the parents
We designed an implementation and satisfaction questionnaire for the parents. It covers the subject's dosage, quality, adaption, responsiveness and program differentiation.
Once after treatment (t1, after 14 weeks)
Implementation and satisfaction questionnaire for the therapist
We designed an implementation and satisfaction questionnaire for the therapist. Questions regarding whether the intervention was being delivered as written (adherence) and the representativeness of the participants (reach) were implemented in the therapist's questionnaire covering questions like "The psychoeducation/relapse prophylaxis/exposure sessions were carried out as planned." and a checklist regarding information e.g. about the socioeconomic status, age, gender or IQ.
Once after treatment (t1, after 14 weeks)
Secondary Outcomes (19)
Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Children's Global Assessment Scale (CGAS)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Clinical Global Impressions-Improvement (CGI-I)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Clinical Global Impressions-Severity (CGI-S)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
Children's DIPS Open Access: Diagnostic Interview in Childhood and Adolescent Mental Disorders (Kinder-DIPS)
Baseline (before treatment (t0)) and after treatment (t1, after 14 weeks)
- +14 more secondary outcomes
Study Arms (1)
Treatment with cbt
EXPERIMENTALTreatment for 26 patients with obsessive-compulsive disorder, 14 sessions, each about 90 minutes.
Interventions
26 patients with obsessive-compulsive disorder (OCD) receive treatment with cognitive-behavioral therapy. 14 sessions will take place via the internet.
Eligibility Criteria
You may qualify if:
- children and adolescents with obsessive-compulsive disorders
- aged 12 to 18 years
- a primary DSM-5 obsessive-compulsive disorder
- at least one primary caretaker
- German-speaking (child \& caretakers)
- family home equipped with broadband internet connection
- written informed consent of the child and its caretakers
- psychiatric comorbidities will be allowed as long as the comorbid disorder does not have a higher treatment priority than OCD (i.e., psychosis, eating disorder and severe depression)
- Medication is allowed if treatment was stable for 6 weeks before diagnostics and will then be taken during the trial.
You may not qualify if:
- IQ below 70
- patients do not speak or understand German
- patients have a psychiatric comorbidity or suicidality that makes participation clinically inappropriate
- too seriously ill so that they should be treated in the hospital
- stable social environment, able to support the children adequately during therapy. - drug addiction
- if the family seems to be severely psychologically burdened so that participation in the sessions and support of the children during the trial will not be possible
- no other psychological treatment is allowed
- If reporting side effects or circumstances that make iCBT treatment clinically inappropriate, or if wished by the patients, the patients are excluded from the study and transferred to another more appropriate therapy option.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Hospital Tuebingenlead
- Universität Tübingencollaborator
- University of Hohenheimcollaborator
Study Sites (1)
Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy
Tübingen, Baden-Wurttemberg, 72076, Germany
Related Publications (5)
Hollmann K, Allgaier K, Hohnecker CS, Lautenbacher H, Bizu V, Nickola M, Wewetzer G, Wewetzer C, Ivarsson T, Skokauskas N, Wolters LH, Skarphedinsson G, Weidle B, de Haan E, Torp NC, Compton SN, Calvo R, Lera-Miguel S, Haigis A, Renner TJ, Conzelmann A. Internet-based cognitive behavioral therapy in children and adolescents with obsessive compulsive disorder: a feasibility study. J Neural Transm (Vienna). 2021 Sep;128(9):1445-1459. doi: 10.1007/s00702-021-02409-w. Epub 2021 Aug 25.
PMID: 34432173BACKGROUNDKlein CS, Seyboth L, Conzelmann A, Schroder PA, Alt AK, Pascher A, Renner TJ, Gawrilow C, Hollmann K. Moderators of Symptom Self-Ratings in Pediatric Patients with Obsessive-Compulsive Disorder During a Digital Sensor-Assisted Treatment. Child Psychiatry Hum Dev. 2025 Nov 14. doi: 10.1007/s10578-025-01924-1. Online ahead of print.
PMID: 41236692DERIVEDAlt AK, Klein CS, Pascher A, Conzelmann A, Kosel F, Kuhnhausen J, Hollmann K, Renner TJ. Acceptance of a sensor-based online psychotherapy for adolescents with obsessive-compulsive disorder (SSTeP-KiZ). Digit Health. 2025 Mar 28;11:20552076251327046. doi: 10.1177/20552076251327046. eCollection 2025 Jan-Dec.
PMID: 40162174DERIVEDKlein CS, Alt AK, Pascher A, Kuhnhausen J, Seizer L, Ilg W, Thierfelder A, Primbs J, Menth M, Barth GM, Gawrilow C, Conzelmann A, Renner TJ, Hollmann K. Cognitive behavioral therapy for pediatric obsessive-compulsive disorder delivered via internet videoconferencing: a manualized sensor-assisted feasibility approach. Child Adolesc Psychiatry Ment Health. 2024 Dec 4;18(1):154. doi: 10.1186/s13034-024-00844-7.
PMID: 39633405DERIVEDKlein CS, Hollmann K, Kuhnhausen J, Alt AK, Pascher A, Seizer L, Primbs J, Ilg W, Thierfelder A, Severitt B, Passon H, Worz U, Lautenbacher H, Bethge WA, Lochner J, Holderried M, Swoboda W, Kasneci E, Giese MA, Ernst C, Barth GM, Conzelmann A, Menth M, Gawrilow C, Renner TJ. Lessons learned from a multimodal sensor-based eHealth approach for treating pediatric obsessive-compulsive disorder. Front Digit Health. 2024 Sep 24;6:1384540. doi: 10.3389/fdgth.2024.1384540. eCollection 2024.
PMID: 39381777DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Annette Conzelmann, Prof.
University Hospital Tübingen
- PRINCIPAL INVESTIGATOR
Tobias J Renner, Prof.
University Hospital Tübingen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. Tobias Renner, Head of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy
Study Record Dates
First Submitted
December 10, 2021
First Posted
March 22, 2022
Study Start
August 1, 2021
Primary Completion
March 31, 2023
Study Completion
March 31, 2023
Last Updated
September 29, 2023
Record last verified: 2023-09
Data Sharing
- IPD Sharing
- Will not share